LeMaitre Vascular Inc (LMAT)vsResMed Inc (RMD)
LMAT
LeMaitre Vascular Inc
$94.48
+0.98%
HEALTHCARE · Cap: $2.16B
RMD
ResMed Inc
$196.04
+0.89%
HEALTHCARE · Cap: $28.25B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 2061% more annual revenue ($5.54B vs $256.28M). RMD leads profitability with a 27.4% profit margin vs 24.3%. RMD appears more attractively valued with a PEG of 1.15. RMD earns a higher WallStSmart Score of 73/100 (B).
LMAT
Buy63
out of 100
Grade: C+
RMD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-61.0%
Fair Value
$54.53
Current Price
$94.48
$39.95 premium
Margin of Safety
-26.9%
Fair Value
$204.63
Current Price
$196.04
$8.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Keeps 24 of every $100 in revenue as profit
Strong operational efficiency at 26.7%
Earnings expanding 41.7% YoY
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : LMAT
The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 24.3% and operating margin at 26.7%. Revenue growth of 11.2% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : LMAT
The primary concerns for LMAT are P/E Ratio, PEG Ratio.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
RMD carries more volatility with a beta of 0.78 — expect wider price swings.
LMAT is growing revenue faster at 11.2% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (73/100 vs 63/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LeMaitre Vascular Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?